Arcturus Q2 revenue falls sharply on CSL Seqirus deal end

ARCT•2026-08-06

Analyst coverage and valuation

The current average analyst rating on the shares is buy, with 9 strong buy or buy ratings, 3 hold ratings and no sell or strong sell ratings.

The average consensus recommendation for the biotechnology and medical research peer group is buy.

Wall Street's median 12-month price target for Arcturus Therapeutics Holdings Inc is $20.00, about 219.5% above its August 5 closing price of $6.26.

Pipeline updates and 2026 outlook

Arcturus expects a decision on advancing ARCT-032 to Phase 3 in Q4 2026.

The company plans to communicate ARCT-810 data and its regulatory plan in Q3 2026.

Arcturus also said it intends to evaluate development and partnering opportunities for its infectious disease vaccine portfolio.

Metric	Actual
Q2 Collaboration Revenue	$880,000
Q2 Net Loss	$23.79 million
Q2 Loss Per Basic Share	$0.84
Q2 Operating Expenses	$28.50 million
Q2 Operating Income	-$25.55 million

Arcturus Q2 revenue falls sharply on CSL Seqirus deal end

Analyst coverage and valuation

Pipeline updates and 2026 outlook

Loss widens on clinical development costs

Related News

Neuberger Energy Infrastructure and Income Fund announces annual shareholder meeting

Roku beats quarterly revenue estimates on advertising, subscriptions strength

Stagwell director Beth J. Kaplan files initial beneficial ownership statement

Revenue falls as CSL Seqirus collaboration ends

Pitney Bowes SendTech EVP Todd A. Everett sells 25,000 shares worth $451,700

Profound Medical Q2 FY26 net loss narrows 39% to USD 9.5 million; revenue rises 12% to USD 2.5 million